788 related articles for article (PubMed ID: 28176529)
1. Biosimilars: Practical Considerations for Pharmacists.
Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
[TBL] [Abstract][Full Text] [Related]
2. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
4. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
5. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
6. Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists.
Griffith N; McBride A; Stevenson JG; Green L
Hosp Pharm; 2014 Oct; 49(9):813-25. PubMed ID: 25477613
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory diseases: Integrating biosimilars into clinical practice.
Feldman SR
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: Considerations for Oncology Nurses
.
Vizgirda V; Jacobs I
Clin J Oncol Nurs; 2017 Apr; 21(2):E54-E60. PubMed ID: 28315542
[TBL] [Abstract][Full Text] [Related]
12. Developing clinical trials for biosimilars.
Bui LA; Taylor C
Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars: Implications for health-system pharmacists.
Lucio SD; Stevenson JG; Hoffman JM
Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know.
Feldman SR; Bagel J; Namak S
Am J Med Sci; 2018 May; 355(5):411-417. PubMed ID: 29753369
[TBL] [Abstract][Full Text] [Related]
15. A clinician's guide to biosimilars in oncology.
Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
[TBL] [Abstract][Full Text] [Related]
16. The complexities of biosimilars and the regulatory approval process.
Lucio S
Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
[TBL] [Abstract][Full Text] [Related]
17. A survey of pharmacists' knowledge and views of biosimilars in Quebec and France.
Adé A; Bourdon O; Bussières JF
Ann Pharm Fr; 2017 Jul; 75(4):267-275. PubMed ID: 28237527
[TBL] [Abstract][Full Text] [Related]
18. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
[TBL] [Abstract][Full Text] [Related]
19. Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019.
Tan CJ; Ke Y; Chan A
J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):33-39. PubMed ID: 32268830
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
Hung A; Vu Q; Mostovoy L
J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
